Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
AssigneeThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
InventorsRoland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Claims20
A method of treating a subject that has multiple sclerosis comprising,
- administering to the subject a therapeutically effective amount of interferon-beta and a therapeutically effective amount of an antibody that specifically binds an interleukin 2 receptor, thereby treating the subject.
Dependencies are inferred from the claim text.